Meningococcal Disease Prevention and Immunology

Meningococcal disease, caused by the bacterium Neisseria meningitidis, remains a global public health challenge due to its rapid onset and high fatality rate. Preventive strategies centre on vaccination against key capsular serogroups—A, B, C, W and Y—and on the induction of robust, long-lasting immune responses. Conjugate vaccines, which couple polysaccharide capsules to carrier proteins, have transformed control efforts by eliciting strong T-cell-dependent immunity and reducing carriage in adolescents, thereby interrupting transmission chains. Advances in immunology have highlighted the roles of humoral and mucosal antibodies, particularly IgG and IgA, in neutralising meningococci at the nasopharyngeal mucosa and in the bloodstream. Complement activation and opsonophagocytosis remain critical effectors of protection, while novel vaccine platforms such as multivalent outer membrane vesicle formulations aim to broaden coverage against emerging clones. Despite these successes, variable uptake, serogroup shifts and the need for booster doses underscore the importance of ongoing surveillance, immunisation programme optimisation and research into pan-meningococcal antigens.

Research from Nature Portfolio

Recent studies have dissected the kinetics and specificity of antibody responses following vaccination with outer membrane vesicle-based formulations. High-resolution profiling of IgG and IgA reactivities against both recombinant and vesicle-derived antigens demonstrated peak serum antibody titres at ten weeks post-immunisation, followed by a divergence in persistence between antigen classes. Such findings elucidate the mechanism by which vesicle components sustain mucosal immunity beyond the lifespan of recombinant-derived responses, offering a blueprint for next-generation multivalent vaccines capable of cross-protecting against related Neisseria species and atypical serogroups.

Meningococcal Disease Prevention and Immunology publication trend

The graph below shows the total number of articles in meningococcal disease prevention and immunology across all publications each year (not limited to Nature Index journals).

Technical terms

Neisseria meningitidis: A Gram-negative diplococcus responsible for invasive meningitis and septicaemia.

Serogroup: A classification of meningococci based on the chemical structure of their capsular polysaccharides.

Conjugate vaccine: A formulation in which bacterial polysaccharides are covalently linked to a carrier protein to enhance T-cell-dependent immunity.

Outer membrane vesicle (OMV): Nanoscale blebs shed from the bacterial surface that present multiple antigens in their native conformation.

Immunoglobulin: An antibody isotype (such as IgG or IgA) that mediates specific binding and neutralisation of pathogens.

Complement system: A cascade of serum proteins that opsonise bacteria and facilitate their clearance by phagocytes.

References

1. Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Neurology (2023).
2. Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices ― United States, 2023. MMWR Morbidity and Mortality Weekly Report (2024).
3. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Review of Vaccines (2016).
4. Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. The Lancet (2013).